Literature DB >> 29780708

Durvalumab for non-resectable stage IIIB non-small cell lung cancer-a small step or a big leap?

Wolfram C M Dempke1,2, Klaus Fenchel3.   

Abstract

Entities:  

Year:  2018        PMID： 29780708      PMCID： PMC5943223          DOI： 10.21037/tlcr.2018.03.18

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  21 in total

Review 1.  Durvalumab in non-small-cell lung cancer patients: current developments.

Authors:  Laura Mezquita; David Planchard
Journal:  Future Oncol       Date:  2017-11-15       Impact factor: 3.404

2.  Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.

Authors:  Boris Sepesi; David B Nelson; Kyle G Mitchell; Don L Gibbons; John V Heymach; Ara A Vaporciyan; Stephen G Swisher; Jason Roszik
Journal:  Ann Thorac Surg       Date:  2018-03-03       Impact factor: 4.330

Review 3.  Second- and third-generation drugs for immuno-oncology treatment-The more the better?

Authors:  Wolfram C M Dempke; Klaus Fenchel; Peter Uciechowski; Stephen P Dale
Journal:  Eur J Cancer       Date:  2017-02-10       Impact factor: 9.162

4.  Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

Authors:  C A Perez; T F Pajak; P Rubin; J R Simpson; M Mohiuddin; L W Brady; R Perez-Tamayo; M Rotman
Journal:  Cancer       Date:  1987-06-01       Impact factor: 6.860

5.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

6.  Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

Authors:  Jin Seok Ahn; Yong Chan Ahn; Joo-Hang Kim; Chang Geol Lee; Eun Kyung Cho; Kyu Chan Lee; Ming Chen; Dong-Wan Kim; Hoon-Kyo Kim; Young Joo Min; Jin-Hyoung Kang; Jin-Hyuck Choi; Sang-We Kim; Guangying Zhu; Yi-Long Wu; Sung Rok Kim; Kyung Hee Lee; Hong Suk Song; Yoon-La Choi; Jong-Mu Sun; Sin-Ho Jung; Myung-Ju Ahn; Keunchil Park
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

8.  Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination.

Authors:  Francesco Fiorica; Lorenzo Belluomini; Antonio Stefanelli; Alessandra Santini; Benedetta Urbini; Carlotta Giorgi; Antonio Frassoldati
Journal:  Am J Clin Oncol       Date:  2018-11       Impact factor: 2.339

9.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

Review 10.  Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?

Authors:  Wolfram C M Dempke; Ludger Sellmann; Klaus Fenchel; Klaus Edvardsen
Journal:  Anticancer Res       Date:  2015-11       Impact factor: 2.480
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.